Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer

Targeting anti-apoptotic BCL2 family proteins is an attractive therapeutic strategy to drive prostate cancer (PCa) cell death. Here, we show that MCL1 is highly expressed in castration-resistant PCa, associating with worse clinical outcome. We demonstrate that targeting MCL1 with BH3 mimetics triggers apoptotic cell death in a subset of PCa cell line models. Furthermore, siRNA targeting of UCHL3, a deubiquitinating enzyme, downregulates MCL1 expression to synergize with BCLXL blockade; however, its impact on MCL1 is driven through an off-target effect, raising an important methodological consideration when studying MCL1 biology. Finally, we demonstrate that co-targeting MCL1 and BCLXL in patient-derived and mouse PCa models drives apoptotic PCa cell death. Taken together, targeting the intrinsic apoptosis pathway remains an attractive therapeutic strategy for lethal PCa. Future studies should focus on identifying strategies and technologies that can deliver cancer specific kill, to improve the outcome for men with this lethal disease.

Authors

Institutions

Publication Details

Journal
iScience
Published
2025-11-11
DOI
https://doi.org/10.1016/j.isci.2025.113985
Primary Topic
Cell death mechanisms and regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer

Jonathan Welti, Marco Bezzi, Bora Gürel, Daniel Westaby et al.
iScience
Cell death mechanisms and regulation
article

Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer

Jonathan Welti, Marco Bezzi, Bora Gürel, Daniel Westaby, Antje Neeb, Ana Padilha, Florian Gabel, Ines Figueiredo, Denisa Bogdan, Nicole Pandell, Jan Rekowski, Amanda Swain, Susana Miranda, Souvik Das, Adam Sharp, John D. Taylor, Johann Sebastian De Bono, Lorenzo Buroni, Suzanne Carreira, Steven P. Balk, Emily Hobern, Wei Yuan, Timothy H. Goldsmith, Juan M. Jiménez-Vacas, Nick Waldron, Maryou B. Lambros, Wanting Zeng
article en

Abstract

Targeting anti-apoptotic BCL2 family proteins is an attractive therapeutic strategy to drive prostate cancer (PCa) cell death. Here, we show that MCL1 is highly expressed in castration-resistant PCa, associating with worse clinical outcome. We demonstrate that targeting MCL1 with BH3 mimetics triggers apoptotic cell death in a subset of PCa cell line models. Furthermore, siRNA targeting of UCHL3, a deubiquitinating enzyme, downregulates MCL1 expression to synergize with BCLXL blockade; however, its impact on MCL1 is driven through an off-target effect, raising an important methodological consideration when studying MCL1 biology. Finally, we demonstrate that co-targeting MCL1 and BCLXL in patient-derived and mouse PCa models drives apoptotic PCa cell death. Taken together, targeting the intrinsic apoptosis pathway remains an attractive therapeutic strategy for lethal PCa. Future studies should focus on identifying strategies and technologies that can deliver cancer specific kill, to improve the outcome for men with this lethal disease.

iScienceVol. 28(12)
Beth Israel Deaconess Medical Center (US), Royal Marsden NHS Foundation Trust (GB), Institute of Cancer Research (GB)
Openalex Percentile: Top 70%
Cell death mechanisms and regulation
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.